MIN 117

Drug Profile

MIN 117

Alternative Names: MIN-117; Wf-516; WF516

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Minerva Neurosciences
  • Class Antidepressants; Oxadiazoles; Piperidines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor modulators; Serotonin 1A receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 09 Apr 2018 Phase-II clinical trials in Major depressive disorder in USA (PO) (NCT03446846)
  • 12 Mar 2018 Minerva neurosciences completes a phase I food effect trial
  • 06 Nov 2017 Minerva Neurosciences plans to initiate a phase IIb trial of MIN 117 for Major depressive disorder (including mood and anxiety disorders) in USA by early 2018 (PO) (NCT03446846)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top